Cancer Genetics – News and Features

A study from Arizona State University links glyphosate, a widely used herbicide, to Alzheimer’s-like brain damage and persistent neuroinflammation in mice. Findings show lasting effects even at regulatory "safe" doses.

MSK researchers discovered that aging cells mimic iron deficiency, reducing their ability to regenerate and develop cancer. However, this also makes older cells more resistant to therapies like ferroptosis.

A study from Spain’s CNIO identifies genetic alterations linked to STAG2 loss, driving aggressiveness in Ewing sarcoma. These changes increase metastasis and impact immune response, offering new prognostic markers and therapeutic targets.

Researchers revealed that checkpoint inhibitors, a powerful cancer immunotherapy, impair B cell function, reducing antibody diversity and increasing infection risk. They suggest immunoglobulin replacement therapy as a preventive measure.

Researchers have revealed how IDH mutations in gliomas act as a "ticking time bomb," initiating slow growth before genetic mutations drive aggressive cancer progression. The study highlights epigenetic immune suppression and cellular shifts.

T-cell dysfunction linked to obesity prevents T cells from detecting tumor cells, increasing cancer risk.

New research shows that a single BRCA1 mutation is sufficient to promote breast cancer by making breast cells more susceptible to tumor growth. This finding redefines the two-hit model of cancer development.

A new model for studying breast cancer could help researchers better understand why and where it metastasizes.

Stanford Medicine researchers discovered that extrachromosomal DNA (ecDNA) significantly drives cancer growth. By analyzing nearly 15,000 human cancers, they found that ecDNAs impact tumor behavior and can be targeted with therapies.

Researchers have identified how mutations to CDK12 drive prostate cancer development and reported a promising treatment that targets the gene.